The Latest Breaking News from Pfizer

Here's a roundup of top developments in the biotech space over the last 24 hours:

Pfizer Inc (NYSE:PFE) shared additional data from the Phase 2/3 EPIC-SR study of Paxlovid (nirmatrelvir and ritonavir tablets) in patients at standard risk for developing severe COVID-19.  In previously reported interim analyses, the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met. Non-significant 70% relative…

A government advisory panel is meeting to decide whether to recommend a second brand of COVID-19 vaccine for school-age children and teens

Advisors to the FDA unanimously Tuesday recommended expanding Moderna's Covid vaccine to children as young as 6.

Following an independent expert report suggesting that Australia-based ResApp Health Limited's current share price was undervalued, Pfizer Inc (NYSE: PFE) bolstered its takeover bid.

Here's a roundup of top developments in the biotech space over the last 24 hours:

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 23 strange trades.

FDA staffers said Pfizer's and Moderna's pediatric Covid vaccines are safe and effective, but both vaccine stocks toppled Monday.

Biotech may be one of the biggest beneficiaries of artificial intelligence and machine learning.